There's more to work than life.

The terms of the deal, Harrington said, was that Valve would fund all but $1 million of the development costs of Half-Life's sequels, with Sierra retaining IP rights and giving Valve back 15% of ...

Phase 1 clinical trial of its investigational half-life extended anti-IL-23 monoclonal antibody, SPY003. This milestone marks our fourth on-time clinical trial initiation in nine months.